114 related articles for article (PubMed ID: 2310989)
1. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
Kalin ML; Babich MF; Klinke WP; Hui WK
Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989
[TBL] [Abstract][Full Text] [Related]
2. Comparative bioavailability of two oral sustained-release procainamide products.
Baker BA; Reynolds JR; Gleckel L; A'Zary E; Bodenheimer MM
Clin Pharm; 1988 Feb; 7(2):135-8. PubMed ID: 3349748
[TBL] [Abstract][Full Text] [Related]
3. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
Zema MJ; Mirando T
Angiology; 1983 Jan; 34(1):32-9. PubMed ID: 6186164
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization.
Yang BB; Abel RB; Uprichard AC; Smithers JA; Forgue ST
J Clin Pharmacol; 1996 Jul; 36(7):623-33. PubMed ID: 8844445
[TBL] [Abstract][Full Text] [Related]
5. Experiences on a sustained-release procainamide preparation.
Ruosteenoja R; Torsti P; Sothmann A
Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
[No Abstract] [Full Text] [Related]
6. [Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets].
Henningsen P; Laursen HB; Christiansen BD; Moller J
Ugeskr Laeger; 1976 Sep; 138(40):2433-7. PubMed ID: 968997
[No Abstract] [Full Text] [Related]
7. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
Bliddal J
Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
[No Abstract] [Full Text] [Related]
8. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
Pirovino M; Karlaganis G; Galeazzi RL
Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144
[TBL] [Abstract][Full Text] [Related]
9. Sustained-release procainamide: use of serum concentrations to determine dosage.
Reed WE; Cooper MW
South Med J; 1985 Oct; 78(10):1190-3. PubMed ID: 4049036
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of an open-loop, computer-based infusion system designed to achieve a series of constant, targeted plasma procainamide concentrations in patients undergoing electrophysiologic testing.
Coyle JD; Carnes CA; Schaal SF
Pharmacotherapy; 1997; 17(3):445-56. PubMed ID: 9165549
[TBL] [Abstract][Full Text] [Related]
11. Procainamide in plasma following administration of sustained-release tablets in acute myocardial infarction.
Ihlen H; Skomedal T; Stafsnes H; Ditlefsen EM
Curr Ther Res Clin Exp; 1975 Mar; 17(3):257-62. PubMed ID: 805020
[No Abstract] [Full Text] [Related]
12. The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy.
Yamazaki M; Fukutomi O; Kondo N; Kato Z; Nakashima Y; Shinoda S; Agata H; Kondo T; Imaeda N; Orii T
Int J Clin Pharmacol Ther; 1994 Nov; 32(11):625-31. PubMed ID: 7874380
[TBL] [Abstract][Full Text] [Related]
13. Thrombocytopenia following sustained-release procainamide.
Meisner DJ; Carlson RJ; Gottlieb AJ
Arch Intern Med; 1985 Apr; 145(4):700-2. PubMed ID: 2580499
[TBL] [Abstract][Full Text] [Related]
14. Conventional and sustained-release procainamide: update on pharmacology and clinical use.
Anderson JL
Clin Ther; 1985; 7(5):618-40. PubMed ID: 3902240
[TBL] [Abstract][Full Text] [Related]
15. [Verification of therapeutic levels of procainamide and N-acetyl- procainamide in ventricular arrhythmia].
Sinkiewicz W; Marzec A; Jankowski A; Hoffmann A; Makuch K; Romański B
Pol Tyg Lek; 1990 Jun 4-11; 45(23-24):458-60. PubMed ID: 1703654
[TBL] [Abstract][Full Text] [Related]
16. Myocardial uptake and pharmacodynamics of procainamide in patients with coronary heart disease and sustained ventricular tachyarrhythmias.
Gillis AM; Duff HJ; Mitchell LB; Wyse DG
J Pharmacol Exp Ther; 1993 Aug; 266(2):1001-6. PubMed ID: 8355178
[TBL] [Abstract][Full Text] [Related]
17. Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride.
Kasmer RJ; Nara AR; Green JA; Chawla AK; Fleming GM
Drug Intell Clin Pharm; 1987 Feb; 21(2):183-6. PubMed ID: 3829910
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment.
Moffett BS; Cannon BC; Friedman RA; Kertesz NJ
Pharmacotherapy; 2006 Dec; 26(12):1687-93. PubMed ID: 17125432
[TBL] [Abstract][Full Text] [Related]
19. The time to reach steady state after the administration of intravenous bolus, constant infusion, and oral immediate-release and sustained-release preparations.
Chow MS; Sun H
Pharmacotherapy; 1990; 10(6):400-5. PubMed ID: 2287561
[TBL] [Abstract][Full Text] [Related]
20. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
